Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Int J Biol Markers. 2011 Sep 21;26(3):141–152. doi: 10.5301/JBM.2011.8613

Fig. 6.

Fig. 6

Performance of multimarker panels for the discrimination of pancreatic cancer patients from benign controls. The top performing urine and serum biomarker panels for the discrimination of pancreatic cancer patients from benign controls were identified using the Metropolis-Monte Carlo (MMC) algorithm. The best urine panel consisted of CA 125, insulin, and H-FABP while the top serum biomarker panel consisted of sICAM-1, TIMP-1, TIMP-4, CA 125, and CA 19-9. The addition of serum CA 19-9 to the urine panel resulted in optimal performance.